0000899243-17-028412.txt : 20171211 0000899243-17-028412.hdr.sgml : 20171211 20171211151921 ACCESSION NUMBER: 0000899243-17-028412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171211 FILED AS OF DATE: 20171211 DATE AS OF CHANGE: 20171211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEBER ECKARD CENTRAL INDEX KEY: 0001279800 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35119 FILM NUMBER: 171249389 MAIL ADDRESS: STREET 1: C/O DOMAIN ASSOCIATES STREET 2: ONE PALO SQ CITY: PRINCETON STATE: NJ ZIP: 08542 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ocera Therapeutics, Inc. CENTRAL INDEX KEY: 0001274644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 631192270 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 555 TWIN DOLPHIN DRIVE STREET 2: SUITE 615 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 6504750158 MAIL ADDRESS: STREET 1: 555 TWIN DOLPHIN DRIVE STREET 2: SUITE 615 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: TRANZYME INC DATE OF NAME CHANGE: 20031230 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-12-11 0 0001274644 Ocera Therapeutics, Inc. OCRX 0001279800 WEBER ECKARD C/O OCERA THERAPEUTICS, INC. 555 TWIN DOLPHIN DRIVE, SUITE 615 REDWOOD CITY CA 94065 1 0 0 0 Common Stock 2017-12-11 4 D 0 344719 1.52 D 0 I By Trust Common Stock 2017-12-11 4 D 0 11969 1.52 D 0 I By Trust Common Stock 2017-12-11 4 D 0 12500 1.52 D 0 D Stock Option (Right to Buy) 1.84 2017-12-11 4 D 0 2992 D 2019-02-11 Common Stock 2992 0 D Stock Option (Right to Buy) 1.84 2017-12-11 4 D 0 2992 D 2020-02-11 Common Stock 2992 0 D Stock Option (Right to Buy) 7.85 2017-12-11 4 D 0 20000 D 2023-12-19 Common Stock 20000 0 D Stock Option (Right to Buy) 7.84 2017-12-11 4 D 0 10000 D 2024-06-11 Common Stock 10000 0 D Stock Option (Right to Buy) 3.76 2017-12-11 4 D 0 10000 D 2025-06-17 Common Stock 10000 0 D Stock Option (Right to Buy) 2.26 2017-12-11 4 D 0 12500 D 2026-06-13 Common Stock 12500 0 D Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. These shares are indirectly held by the Eckard Weber as Trustee of the Living Trust UTA dated November 20, 2007 Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. (Continued from Footnote 5) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. This Out of the Money Option, which became fully vested on January 1, 2013, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $1.84, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. This Out of the Money Option, which became fully vested on January 1, 2014, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $1.84, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration. This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. /s/ Michael Byrnes, Attorney-In-Fact 2017-12-11